Informations générales (source: ClinicalTrials.gov)
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation
Interventional
Phase 1
Genentech, Inc. (Voir sur ClinicalTrials)
novembre 2024
mai 2028
02 juin 2026
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and
expansion study designed to evaluate the safety, pharmacokinetics, and preliminary
activity of GDC-7035 as a single agent and in combination with other anti-cancer
therapies in participants with advanced or metastatic solid tumors that harbor the KRAS
G12D mutation.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Antoine HOLLEBECQUE | 05/06/2026 06:50:05 | Contacter | ||
Critères
Tous
- Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation
- Agreement to adhere to the contraception requirements described in the protocol for
participants of childbearing potential and participants who produce sperm
Exclusion criteria:
- Malabsorption or other condition that would interfere with enteral absorption
- Active brain metastases
- Clinically significant cardiovascular dysfunction or liver disease